Co-Diagnostics’s Return On Capital Employed Insights
Pulled from Benzinga Pro data, Co-Diagnostics (NASDAQ:CODX) posted Q4 earnings of $7.50 million, an increase from Q3 of 34.66%. Sales dropped to $20.40 million, a 32.22% decrease between quarters.